Soligenix, Inc. Common Stock (NASDAQ:SNGX) shares rose 5.1% during mid-day trading on Tuesday . The stock traded as high as $1.07 and last traded at $1.03. Approximately 539,400 shares were traded during mid-day trading, an increase of 328% from the average daily volume of 126,172 shares. The stock had previously closed at $0.98.
SNGX has been the topic of several research analyst reports. HC Wainwright set a $3.00 price objective on Soligenix, Inc. Common Stock and gave the stock a “hold” rating in a research note on Friday, March 16th. Maxim Group set a $5.00 target price on Soligenix, Inc. Common Stock and gave the stock a “buy” rating in a report on Thursday, March 15th. Finally, ValuEngine upgraded Soligenix, Inc. Common Stock from a “strong sell” rating to a “sell” rating in a report on Wednesday, May 2nd.
Soligenix, Inc. Common Stock (NASDAQ:SNGX) last posted its earnings results on Friday, May 11th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.02. The company had revenue of $1.10 million during the quarter. Soligenix, Inc. Common Stock had a negative return on equity of 182.10% and a negative net margin of 149.71%. sell-side analysts anticipate that Soligenix, Inc. Common Stock will post -1.1 EPS for the current fiscal year.
About Soligenix, Inc. Common Stock
Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that has completed Phase II clinical trial to treat oral mucositis in head and neck cancer.
No comments:
Post a Comment